Anton P. Porsteinsson
A5033585095- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Schizophrenia research and treatment
- Cholinesterase and Neurodegenerative Diseases
- Attention Deficit Hyperactivity Disorder
- Health, Environment, Cognitive Aging
- Treatment of Major Depression
- Healthcare Decision-Making and Restraints
- Advanced Neuroimaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Epilepsy research and treatment
- Bioinformatics and Genomic Networks
- Neurological Disease Mechanisms and Treatments
- Genetic Associations and Epidemiology
- Cognitive Functions and Memory
- Mental Health and Psychiatry
- Pharmacological Effects and Toxicity Studies
- Diet and metabolism studies
- Neurological Disorders and Treatments
- EEG and Brain-Computer Interfaces
- Memory and Neural Mechanisms
- Psychosomatic Disorders and Their Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Brain Tumor Detection and Classification
University of Rochester
2016-2025
Intuit (United States)
2024-2025
University of Rochester Medical Center
2015-2024
Alzheimer’s Disease Neuroimaging Initiative
2023-2024
San Francisco VA Medical Center
2024
University of California, San Francisco
2024
Cohort (United Kingdom)
2023
Medical University of South Carolina
2017
Sunnybrook Hospital
2017
Sunnybrook Research Institute
2017
Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.
Agitation is common, persistent, and associated with adverse consequences for patients Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.The primary objective was to evaluate the efficacy of citalopram agitation in Key secondary objectives examined effects on function, caregiver distress, safety, cognitive tolerability.The Citalopram Disease Study (CitAD) a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186...
Abstract Alzheimer’s Disease (AD) is a progressive neurodegenerative disease where biomarkers for based on pathophysiology may be able to provide objective measures diagnosis and staging. Neuroimaging scans acquired from MRI metabolism images obtained by FDG-PET in-vivo measurements of structure function (glucose metabolism) in living brain. It hypothesized that combining multiple different image modalities providing complementary information could help improve early AD. In this paper, we...
Agitation is common across neuropsychiatric disorders and contributes to disability, institutionalization, diminished quality of life for patients their caregivers. There no consensus definition agitation widespread agreement on what elements should be included in the syndrome. The International Psychogeriatric Association formed an Definition Work Group (ADWG) develop a provisional with cognitive that can applied epidemiologic, non-interventional clinical, pharmacologic, non-pharmacologic...
Abstract Objectives To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions solanezumab, an anti‐β‐amyloid (Aβ) antibody, in patients with mild‐to‐moderate Alzheimer's disease. Cognitive measures were also obtained. Methods In this phase 2, randomized, double‐blind, placebo‐controlled clinical trial, 52 disease received placebo or antibody (100 mg every 4 weeks, 100 weekly, 400 weekly) for weeks. Safety biomarker evaluations continued until 1 year...
This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).A total 353 patients were randomized (250, 1,000, or 2,000 mg) placebo twice daily for 78 weeks. Coprimary endpoints the Neuropsychological Test Battery (NTB) Alzheimer's Disease Cooperative Study-Activities Daily Living (ADCS-ADL) scale. The primary analysis compared 250...
Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking.To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for disease-related agitation.Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design consecutive 5-week treatment stages conducted August 2012-August 2014. Patients probable disease, clinically significant agitation (Clinical Global...
Apathy is common in neurocognitive disorders (NCD) but NCD-specific diagnostic criteria are needed.The International Society for CNS Clinical Trials Methodology Work Group convened an expert group and sought input from academia, health-care, industry, regulatory bodies. A modified Delphi methodology was followed, included extensive literature review, two surveys, meetings at international conferences, culminating a consensus meeting 2019.The final reached with more than 80% agreement on all...
Accumulation of tau pathology in Alzheimer disease (AD) correlates with cognitive decline. Anti-tau immunotherapies were proposed as potential interventions AD. While antibodies targeting N-terminal failed to demonstrate clinical efficacy prodromal-to-mild AD, their utility at other stages was not evaluated prior studies. Lauriet is a phase 2 study an anti-tau monoclonal antibody, semorinemab, patients mild-to-moderate
LY450139 dihydrate, a gamma-secretase inhibitor, was studied in randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 5 weeks. Treatment well tolerated. Abeta(1-40) plasma decreased 38.2%; CSF, 4.42 +/- 9.55% (p = not significant). Higher drug doses may result additional decreases Abeta concentrations and measurable decrease CSF Abeta.
Objective: To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimers disease (AD) receiving cholinesterase inhibitor (ChEI) treatment. Methods: Participants (N= 433) probable AD, Mini-Mental State Exam (MMSE) scores between 10-22 (inclusive), concurrent stable use ChEIs (donepezil, rivastigmine, galantamine) were randomized placebo or (20 mg once daily) for 24 weeks. Primary outcomes changes from baseline on Disease Assessment Scale-cognitive subscale...
Neuropsychiatric symptoms (NPS) affect almost all patients with dementia and are a major focus of study treatment. Accurate assessment NPS through valid, sensitive reliable measures is crucial. Although current have many strengths, they also some limitations (e.g. acquisition data limited to informants or caregivers as respondents, depth items specific moderate dementia). Therefore, we developed revised version the NPI, known NPI-C. The NPI-C includes expanded domains items, clinician-rating...
Regions of the temporal and parietal lobes are particularly damaged in Alzheimer's disease (AD), this leads to a predictable pattern brain atrophy. In vivo quantification subregional atrophy, such as changes cortical thickness or structure volume, could lead improved diagnosis better assessment neuroprotective effects therapy. Toward end, we have developed fast robust method for accurately quantifying cerebral structural several subcortical regions using serial MRI scans. 169 healthy...
<h3>Context</h3>Agitation and psychosis are common in Alzheimer disease cause considerable morbidity. We attempted to delay or prevent agitation with the use of divalproex sodium (valproate).<h3>Objective</h3>To determine whether treatment valproate could emergence psychosis.<h3>Design, Setting, Patients</h3>A multicenter, randomized, double-blind, placebo-controlled trial flexible-dose 313 (of 513 screened) individuals moderate who had not yet experienced psychosis. The study was conducted...
<h3>Objective:</h3> To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using <sup>11</sup>C-Pittsburgh compound B (<sup>11</sup>C-PiB)-PET. <h3>Methods:</h3> Two phase 3 clinical trials, 1 each in apolipoprotein <i>APOE</i> ε4 carriers and noncarriers, were conducted patients with mild to moderate Alzheimer disease dementia. Bapineuzumab, an anti-Aβ monoclonal antibody, or placebo, was administered by IV infusion every 13 weeks for 78 weeks. PET substudies assessed change...
<h3>Objective:</h3> We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia. <h3>Methods:</h3> In phase 3, double-blind, placebo-controlled trial, we randomly assigned 390 participants with AD receive placebo (low-dose albumin) or IVIg (Gammagard Liquid; Baxalta, Bannockburn, IL) administered at doses 0.2 0.4 g/kg every 2 weeks 18 months. The primary cognitive outcome was change from baseline months on the 11-item...